Biotech News

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income

Amarin Corporation (AMRN)Amarin CorporationEarnings

Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.

Related news

Amarin Corporation

Cardiovascular Therapeutics Company Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl. Its commercial strategy combines a continuing U.S. presence with regional partners responsible for regulatory, market-access, and sales activities internationally. VASCEPA and VAZKEPA The product is...

Recent company news

Stock data

Close
11.26 USD
Market cap
303.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States